semaglutide vision A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no Risk of nonarteritic anterior ischemic

However, key impurities, such as Aspartate isomerization to isoAsp or racemization (D-amino acid formation), have the same mass and cannot be distinguished by mass alone

Because of this, there is not much data about the risks over a long time

Among them, resveratrol, icariin, epigallocatechin-3-gallate, ginsenoside, sinomenine, paeoniflorin, triptolide and paeoniflorin are star natural medicines for the treatment of RA

doi:10.1080/19396368.2016.1246623

Heavy pharma investment in GLP-1 receptor agonists (35% of obesity drugs in development) highlights their potential to shift the standard of care for a range of diseases